FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170063492> ?p ?o ?g. }

• W3170063492 endingPage "10" @default.
• W3170063492 startingPage "1" @default.
• W3170063492 abstract "Muscle-invasive bladder cancer (MIBC) remains undertreated despite multiple potentially curative options. Both radical cystectomy (RC) with or without neoadjuvant chemotherapy and trimodal therapy (TMT), including transurethral resection of bladder tumor followed by chemoradiotherapy, are standard treatments.To evaluate real-world clinical outcomes of RC with neoadjuvant chemotherapy (RC-NAC), RC without NAC, TMT with National Comprehensive Cancer Network guideline-preferred radiosensitizing chemotherapy including cisplatin or mitomycin-C and 5-fluorouracil (pTMT), and TMT with nonpreferred chemotherapy (npTMT).US veterans with nonmetastatic MIBC (T2-4aN0-3M0) were studied.Overall mortality (OM) was evaluated with multivariable Cox proportional hazard model. Bladder cancer-specific mortality (BCSM) was evaluated with multivariable Fine-Gray regression. Salvage cystectomy rates were obtained by chart review.Overall 2306 patients were included: 1472 (64%) with RC without NAC, 506 (22%) with RC-NAC, 163 (7%) with pTMT, and 165 (7%) with npTMT. On multivariable analysis, pTMT was associated with similar OM (hazard ratio [HR] 1.19; 95% confidence interval [CI] 0.94-1.50; p = 0.15) and BCSM (HR 1.34; 95% CI 0.99-1.83; p = 0.06) to RC-NAC; npTMT was associated with worse OM (HR 1.30; 95% CI 1.04-1.61; p = 0.02) and BCSM (HR 1.45; 95% CI 1.09-1.94; p = 0.01). RC without NAC was associated with similar OM (HR 1.08; 95% CI 0.95-1.24; p = 0.24) and BCSM (HR 1.02; 95% CI 0.86-1.21; p = 0.79). When stratified by age, among patients ≥65 yr of age, treatment with pTMT was associated with similar OM (HR 1.14; 95% CI 0.87-1.50; p = 0.35) and BCSM (HR 1.11; 95% CI 0.76-1.62; p = 0.60). Among patients <65 yr of age, pTMT was associated with worse OM (HR 1.82; 95% CI 1.14-2.91; p = 0.01) and BCSM (HR 2.51; 95% CI 1.52-4.13; p < 0.01). The 5-yr cumulative incidence of salvage cystectomy in the TMT group was 3.6%.In MIBC, patients receiving pTMT have comparable survival in RC-NAC patients ≥65 yr and inferior survival in RC-NAC patients <65 yr. Salvage cystectomy rates were low.Management of muscle-invasive bladder cancer is a multidisciplinary effort requiring thoughtful discussions with patients about treatment options, including trimodal therapy, which is an effective treatment option." @default.
• W3170063492 created "2021-06-22" @default.
• W3170063492 creator A5004819903 @default.
• W3170063492 creator A5005146231 @default.
• W3170063492 creator A5016475638 @default.
• W3170063492 creator A5043763331 @default.
• W3170063492 creator A5044071754 @default.
• W3170063492 creator A5048513152 @default.
• W3170063492 creator A5053824837 @default.
• W3170063492 creator A5058325420 @default.
• W3170063492 creator A5059026108 @default.
• W3170063492 creator A5083199205 @default.
• W3170063492 creator A5084204364 @default.
• W3170063492 date "2021-08-01" @default.
• W3170063492 modified "2023-10-02" @default.
• W3170063492 title "Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans" @default.
• W3170063492 cites W1800122197 @default.
• W3170063492 cites W1971903914 @default.
• W3170063492 cites W1975848770 @default.
• W3170063492 cites W2029790306 @default.
• W3170063492 cites W2045062819 @default.
• W3170063492 cites W2065741451 @default.
• W3170063492 cites W2092600619 @default.
• W3170063492 cites W2164361265 @default.
• W3170063492 cites W2571353830 @default.
• W3170063492 cites W2605794623 @default.
• W3170063492 cites W2606173101 @default.
• W3170063492 cites W2611553464 @default.
• W3170063492 cites W2781043244 @default.
• W3170063492 cites W2810144280 @default.
• W3170063492 cites W2903199129 @default.
• W3170063492 cites W2903479714 @default.
• W3170063492 cites W2941090869 @default.
• W3170063492 cites W2944891078 @default.
• W3170063492 cites W3001534873 @default.
• W3170063492 cites W3093100665 @default.
• W3170063492 doi "https://doi.org/10.1016/j.euros.2021.05.009" @default.
• W3170063492 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8317783" @default.
• W3170063492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34337540" @default.
• W3170063492 hasPublicationYear "2021" @default.
• W3170063492 type Work @default.
• W3170063492 sameAs 3170063492 @default.
• W3170063492 citedByCount "10" @default.
• W3170063492 countsByYear W31700634922022 @default.
• W3170063492 countsByYear W31700634922023 @default.
• W3170063492 crossrefType "journal-article" @default.
• W3170063492 hasAuthorship W3170063492A5004819903 @default.
• W3170063492 hasAuthorship W3170063492A5005146231 @default.
• W3170063492 hasAuthorship W3170063492A5016475638 @default.
• W3170063492 hasAuthorship W3170063492A5043763331 @default.
• W3170063492 hasAuthorship W3170063492A5044071754 @default.
• W3170063492 hasAuthorship W3170063492A5048513152 @default.
• W3170063492 hasAuthorship W3170063492A5053824837 @default.
• W3170063492 hasAuthorship W3170063492A5058325420 @default.
• W3170063492 hasAuthorship W3170063492A5059026108 @default.
• W3170063492 hasAuthorship W3170063492A5083199205 @default.
• W3170063492 hasAuthorship W3170063492A5084204364 @default.
• W3170063492 hasBestOaLocation W31700634921 @default.
• W3170063492 hasConcept C121608353 @default.
• W3170063492 hasConcept C126322002 @default.
• W3170063492 hasConcept C126894567 @default.
• W3170063492 hasConcept C143998085 @default.
• W3170063492 hasConcept C207103383 @default.
• W3170063492 hasConcept C2775910329 @default.
• W3170063492 hasConcept C2776694085 @default.
• W3170063492 hasConcept C2778239845 @default.
• W3170063492 hasConcept C2780352672 @default.
• W3170063492 hasConcept C44249647 @default.
• W3170063492 hasConcept C50382708 @default.
• W3170063492 hasConcept C71924100 @default.
• W3170063492 hasConceptScore W3170063492C121608353 @default.
• W3170063492 hasConceptScore W3170063492C126322002 @default.
• W3170063492 hasConceptScore W3170063492C126894567 @default.
• W3170063492 hasConceptScore W3170063492C143998085 @default.
• W3170063492 hasConceptScore W3170063492C207103383 @default.
• W3170063492 hasConceptScore W3170063492C2775910329 @default.
• W3170063492 hasConceptScore W3170063492C2776694085 @default.
• W3170063492 hasConceptScore W3170063492C2778239845 @default.
• W3170063492 hasConceptScore W3170063492C2780352672 @default.
• W3170063492 hasConceptScore W3170063492C44249647 @default.
• W3170063492 hasConceptScore W3170063492C50382708 @default.
• W3170063492 hasConceptScore W3170063492C71924100 @default.
• W3170063492 hasFunder F4320332161 @default.
• W3170063492 hasLocation W31700634921 @default.
• W3170063492 hasLocation W31700634922 @default.
• W3170063492 hasLocation W31700634923 @default.
• W3170063492 hasOpenAccess W3170063492 @default.
• W3170063492 hasPrimaryLocation W31700634921 @default.
• W3170063492 hasRelatedWork W1562998603 @default.
• W3170063492 hasRelatedWork W2012557700 @default.
• W3170063492 hasRelatedWork W2563593363 @default.
• W3170063492 hasRelatedWork W2598074874 @default.
• W3170063492 hasRelatedWork W2603025253 @default.
• W3170063492 hasRelatedWork W2765116280 @default.
• W3170063492 hasRelatedWork W2972870493 @default.
• W3170063492 hasRelatedWork W3037879892 @default.
• W3170063492 hasRelatedWork W3144473405 @default.
• W3170063492 hasRelatedWork W3202515919 @default.

• next